PARP inhibitorFDA-approvedSecond-line
Niraparib
How it works
Blocks an enzyme called PARP that helps repair DNA damage in cancer cells, making them more susceptible to cell death.
Cancer types
Pancreatic Cancer— BRCA-mutated
Ovarian Cancer— BRCA1/2-mutated
Efficacy
Niraparib has been shown to improve progression-free survival in BRCA1/2-mutated ovarian cancer patients.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing Niraparib and Copanlisib in Advanced Ovarian and Endometrial Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Niraparib's Safety and Effectiveness in Ovarian Cancer Treatment | Ovarian Cancer | observational | — | Source → |
| Niraparib May Offer Better Progression-Free Survival for Ovarian Cancer Patients | Ovarian Cancer | observational | The median progression-free survival was 13.77 months in the bevacizumab group. | Source → |
| Niraparib May Lower Platelet Count in Ovarian Cancer Patients | Ovarian Cancer | observational | — | Source → |
| Niraparib Safety and Effectiveness in Older Patients with Tubo-Ovarian Cancer | Ovarian Cancer | observational | Progression-free survival was 12 months (95%CI: 2.0-25.0) for patients aged 50-64, 29 months (95%CI: 11.0-52.0) for patients aged 65-74, and 16 months (95%CI: 1.0-31.0) for patients aged 75 and older. | Source → |
| Combining Medications May Help Prostate Cancer Patients | Prostate Cancer | phase-3 | The primary endpoint was met, with a significant improvement in radiographic progression-free survival observed, with a hazard ratio of 0.63. | Source → |
| Ovarian Cancer Cells May Become More Sensitive to Treatment | Ovarian Cancer | lab-study | The resistance indices for A2780/NRP and OVCAR3/NRP were 8.95 and 4.42, respectively. | Source → |
| Corneal Deposits Linked to Cancer Treatment | Ovarian Cancer | observational | — | Source → |
| New Treatment Combination Shows Modest Progression-Free Survival Benefit in Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | The primary endpoint was investigator-assessed progression-free survival (PFS) as per RECIST v1.1, with a median of 20.6 months in arm 3 versus 19.2 months in arm 2. | Source → |
| Ovarian Cancer Treatment Linked to Heart Problems in Some Patients | Ovarian Cancer | lab-study | — | Source → |
| Niraparib Shows Promise in Treating Advanced Melanoma | Melanoma | phase-2 | The disease control rate was 64%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.